DUSP1 and osteosarcoma: Fan et al.22 have shown that upregulated Siglec-15 was associated with the poor clinical outcomes of Osteosarcoma (OS) patients and promoted the proliferation, migration and invasion of OS cells by regulating DUSP1/MAPK Pathway.